Alto Neuroscience, Inc.

Healthcare · Biotechnology · United States

Last price 22.6 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 886.87M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 pro...